A BILL 
To amend the Public Health Service Act to authorize and 
support the creation and dissemination of cardio-
myopathy education, awareness, and risk assessment ma-
terials and resources to identify more at-risk families, 
to authorize research and surveillance activities relating 
to cardiomyopathy, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Cardiomyopathy 
4
Health Education, Awareness, Research, and Training in 
5
the Schools Act of 2020’’ or the ‘‘HEARTS Act of 2020’’. 
6
00:42 Mar 17, 2020
H6166
2 
•HR 6166 IH
SEC. 2. MATERIALS AND RESOURCES TO INCREASE EDU-
1
CATION 
AND 
AWARENESS 
OF 
CARDIO-
2
MYOPATHY AMONG SCHOOL ADMINISTRA-
3
TORS, EDUCATORS, AND FAMILIES. 
4
Part P of title III of the Public Health Service Act 
5
(42 U.S.C. 280g et seq.) is amended by adding at the end 
6
the following new section: 
7
‘‘SEC. 399V–7. MATERIALS AND RESOURCES TO INCREASE 
8
EDUCATION AND AWARENESS OF CARDIO-
9
MYOPATHY AMONG SCHOOL ADMINISTRA-
10
TORS, EDUCATORS, AND FAMILIES. 
11
‘‘(a) MATERIALS AND RESOURCES.—Not later than 
12
18 months after the date of the enactment of this section, 
13
the Secretary, in conjunction with the Director of the Cen-
14
ters for Disease Control and Prevention (in this section 
15
referred to as the ‘Director’) shall develop public education 
16
materials and resources to be disseminated to school ad-
17
ministrators, educators, school health professionals, coach-
18
es, families, guardians, caregivers, and other appropriate 
19
individuals. The materials and resources shall include— 
20
‘‘(1) background information to increase edu-
21
cation and awareness of cardiomyopathy among 
22
school administrators, educators, and families; 
23
‘‘(2) guidelines regarding the placement of 
24
automated external defibrillators in schools, early 
25
00:42 Mar 17, 2020
H6166
3 
•HR 6166 IH
childhood education programs, and child care cen-
1
ters; 
2
‘‘(3) training information on automated exter-
3
nal defibrillators and cardiopulmonary resuscitation; 
4
and 
5
‘‘(4) recommendations for how schools, early 
6
childhood education programs, and child care centers 
7
can develop and implement a cardiac emergency re-
8
sponse plan. 
9
‘‘(b) DISSEMINATION
OF
MATERIALS
AND
RE-
10
SOURCES.—Not later than 30 months after the date of 
11
the enactment of this section, the Secretary, through the 
12
Director, shall disseminate the materials and resources de-
13
veloped under subsection (a) in accordance with the fol-
14
lowing: 
15
‘‘(1) DISTRIBUTION
BY
STATE
EDUCATIONAL 
16
AGENCIES.—The Secretary shall make available such 
17
materials and resources to State educational agen-
18
cies to distribute— 
19
‘‘(A) to school administrators, educators, 
20
school health professionals, coaches, families, 
21
guardians, caregivers, and other appropriate in-
22
dividuals, the cardiomyopathy education and 
23
awareness materials and resources developed 
24
under subsection (a)(1); 
25
00:42 Mar 17, 2020
H6166
4 
•HR 6166 IH
‘‘(B) to parents, guardians, or other care-
1
givers, the risk assessment for individuals with 
2
or at risk for cardiomyopathy developed pursu-
3
ant to section 399V–8(b)(1); and 
4
‘‘(C) to school administrators, educators, 
5
school health professionals, and coaches— 
6
‘‘(i) the guidelines described in sub-
7
section (a)(2); 
8
‘‘(ii) the training information de-
9
scribed in subsection (a)(3); and 
10
‘‘(iii) the recommendations described 
11
in subsection (a)(4). 
12
‘‘(2) DISSEMINATION
TO
HEALTH
DEPART-
13
MENTS AND PROFESSIONALS.—The Secretary shall 
14
make available the materials and resources devel-
15
oped under subsection (a) to State and local health 
16
departments, pediatricians, hospitals, and other 
17
health professionals, such as nurses and first re-
18
sponders. 
19
‘‘(3) POSTING ON WEBSITE.— 
20
‘‘(A) CDC.— 
21
‘‘(i) IN
GENERAL.—The Secretary, 
22
through the Director, shall post the mate-
23
rials and resources developed under sub-
24
section (a) on the public internet website 
25
00:42 Mar 17, 2020
H6166
5 
•HR 6166 IH
of the Centers for Disease Control and 
1
Prevention. 
2
‘‘(ii) ADDITIONAL
INFORMATION.— 
3
The Director is encouraged to maintain on 
4
such public internet website such addi-
5
tional 
information 
regarding 
cardio-
6
myopathy as deemed appropriate by the 
7
Director. 
8
‘‘(B) STATE
EDUCATIONAL
AGENCIES.— 
9
State educational agencies are encouraged to 
10
create public internet webpages dedicated to 
11
cardiomyopathy and post the materials and re-
12
sources developed under subsection (a) on such 
13
webpages. 
14
‘‘(c) DEFINITIONS.—In this section: 
15
‘‘(1) The term ‘school administrator’ means a 
16
principal, director, manager, or other supervisor or 
17
leader within an elementary school, secondary 
18
school, State-based early childhood education pro-
19
gram, or child care center. 
20
‘‘(2) The term ‘school health professional’ 
21
means a health professional serving at an elemen-
22
tary school, secondary school, State-based early 
23
childhood education program, or child care center. 
24
00:42 Mar 17, 2020
H6166
6 
•HR 6166 IH
‘‘(3) The terms ‘early childhood education pro-
1
gram’, ‘elementary school’, and ‘secondary school’ 
2
have the meanings given to those terms in section 
3
8101 of the Elementary and Secondary Education 
4
Act of 1965. 
5
‘‘(d) AUTHORIZATION
OF
APPROPRIATIONS.—For 
6
carrying out this section and section 399V–8, there is au-
7
thorized to be appropriated $1,000,000 for each of fiscal 
8
years 2021 through 2025.’’. 
9
SEC. 3. RESEARCH AND SURVEILLANCE ACTIVITIES RELAT-
10
ING TO CARDIOMYOPATHY. 
11
(a) CDC RESEARCH AND SURVEILLANCE.—Part P 
12
of title III of the Public Health Service Act (42 U.S.C. 
13
280g et seq.), as amended by section 2, is further amended 
14
by adding at the end the following new section: 
15
‘‘SEC. 399V–8. RESEARCH AND SURVEILLANCE ACTIVITIES 
16
RELATING TO CARDIOMYOPATHY. 
17
‘‘(a) 
REPORTS
ON
CDC 
NATIONAL
CARDIO-
18
MYOPATHY SURVEILLANCE RESEARCH ACTIVITIES.— 
19
‘‘(1) INITIAL REPORT.—Not later than June 1, 
20
2021, the Secretary, acting through the Director of 
21
the Centers for Disease Control and Prevention, 
22
shall submit to Congress an initial report on find-
23
ings and data generated from surveillance and re-
24
search activities conducted by the Centers for Dis-
25
00:42 Mar 17, 2020
H6166
7 
•HR 6166 IH
ease Control and Prevention to improve the under-
1
standing of the prevalence and epidemiology of car-
2
diomyopathy across the lifespan, from birth to adult-
3
hood, with particular interest in the following: 
4
‘‘(A) The health care costs, utilization, and 
5
natural history of individuals with cardio-
6
myopathy, in both the pediatric and adult popu-
7
lation. 
8
‘‘(B) The number of adults and children 
9
affected by cardiomyopathy, as well as age-spe-
10
cific mortality. 
11
‘‘(2) FINAL REPORT.—Not later than January 
12
1, 2026, the Secretary, acting through the Director 
13
of the Centers for Disease Control and Prevention, 
14
shall submit to Congress a final report on the con-
15
tent described in paragraph (1). 
16
‘‘(3) PUBLIC
ACCESS.—Subject to paragraph 
17
(4), the reports submitted under this subsection 
18
shall be made available to the public. 
19
‘‘(4) PATIENT PRIVACY.—The Secretary shall 
20
ensure that this subsection is carried out in a man-
21
ner that complies with the requirements applicable 
22
to a covered entity under the regulations promul-
23
gated pursuant to section 264(c) of the Health In-
24
surance Portability and Accountability Act of 1996. 
25
00:42 Mar 17, 2020
H6166
8 
•HR 6166 IH
‘‘(b) IMPROVING RISK ASSESSMENTS FOR INDIVID-
1
UALS WITH CARDIOMYOPATHY.— 
2
‘‘(1) IN
GENERAL.—The Secretary, acting 
3
through the Director of the Centers for Disease 
4
Control and Prevention, shall develop and make pub-
5
licly available a risk assessment for individuals with 
6
or at risk for cardiomyopathy. Such risk assessment 
7
shall, at a minimum, include the following: 
8
‘‘(A) Background information of the preva-
9
lence, incidence, and health impact of cardio-
10
myopathy, including all forms of cardio-
11
myopathy and their effects on pediatric, adoles-
12
cent, and adult individuals. 
13
‘‘(B) A worksheet with variables and con-
14
ditions for an individual or health care provider 
15
to use in assessing whether the individual is at 
16
risk for cardiomyopathy. 
17
‘‘(C) A worksheet with variables and 
18
stages of progression for an individual or health 
19
care provider to use in assessing whether and to 
20
what extent cardiomyopathy has progressed in 
21
the individual. 
22
‘‘(D) 
Guidelines 
on 
cardiomyopathy 
23
screenings for individuals who are at risk for, 
24
or have a family history of, cardiomyopathy. 
25
00:42 Mar 17, 2020
H6166
9 
•HR 6166 IH
‘‘(2) STAKEHOLDER
INPUT.—In carrying out 
1
paragraph (1), the Director of the Centers for Dis-
2
ease Control and Prevention shall seek input from 
3
external stakeholders including— 
4
‘‘(A) representatives from national patient 
5
advocacy organizations expert in all forms of 
6
cardiomyopathy; 
7
‘‘(B) representatives from medical profes-
8
sional societies that specialize in the care of 
9
adults and pediatrics with cardiomyopathy; and 
10
‘‘(C) representatives from other relevant 
11
Federal agencies. 
12
‘‘(c) CARDIOMYOPATHY DEFINED.—For purposes of 
13
this section, the term ‘cardiomyopathy’ means a heart dis-
14
ease that affects the heart’s muscle (myocardium)— 
15
‘‘(1) the symptoms of which may vary from 
16
case to case, including— 
17
‘‘(A) cases in which no symptoms are 
18
present (asymptomatic); and 
19
‘‘(B) cases in which there are symptoms of 
20
a progressive condition that may result from an 
21
impaired ability of the heart to pump blood, 
22
such as fatigue, irregular heartbeats (arrhyth-
23
mia), heart failure, and, potentially, sudden car-
24
diac death; and 
25
00:42 Mar 17, 2020
H6166
10 
•HR 6166 IH
‘‘(2) the recognized types of which include di-
1
lated, hypertrophic, restrictive, arrhythmogenic right 
2
ventricular dysplasia, and left ventricular non-com-
3
paction.’’. 
4
(b) FEDERAL WORKING GROUP.— 
5
(1) IN
GENERAL.—Not later than one year 
6
after the date of the enactment of this Act, the Sec-
7
retary of Health and Human Services shall convene 
8
an interdisciplinary working group for the purpose 
9
of expanding cardiomyopathy research. 
10
(2) DUTIES.—The working group shall— 
11
(A) develop a research strategy to address 
12
the gaps in knowledge on the molecular and ge-
13
netic causes of cardiomyopathy in children; 
14
(B) identify approaches that could result 
15
in the development of preventive and disease-di-
16
rected therapies specific to pediatric cardiomy-
17
opathies and heart failure; and 
18
(C) explore novel clinical trial methodolo-
19
gies and end points in an effort to optimize suc-
20
cessful completion of clinical trials in this rare 
21
patient population. 
22
(3) MEMBERSHIP.—The Secretary shall appoint 
23
to the working group members representing a range 
24
of stakeholders outside of the Federal Government 
25
00:42 Mar 17, 2020
H6166
11 
•HR 6166 IH
with subject matter expertise relating to cardio-
1
myopathy, including— 
2
(A) pediatric cardiologists with expertise in 
3
the diagnosis and treatment of children with 
4
cardiomyopathies and heart failure and clinical 
5
trials related to the pediatric population; 
6
(B) geneticists with expertise in pediatric 
7
cardiomyopathy and heart failure; 
8
(C) cardiovascular molecular biologists; 
9
(D) pharmacologists; 
10
(E) research scientists with expertise in 
11
cardiomyopathy and heart failure; and 
12
(F) other stakeholders with relevant exper-
13
tise, as determined by the Secretary. 
14
(4) REPORT TO CONGRESS.—Not later than 2 
15
years after the date of the enactment of this Act, the 
16
Working Group shall publish and submit to Con-
17
gress a report that contains— 
18
(A) a description of the activities of the 
19
working group; 
20
(B) the findings and recommendations of 
21
the working group with respect to each of the 
22
topics described in paragraph (2); and 
23
(C) the recommendations of the working 
24
group relating to actions that Federal agencies 
25
00:42 Mar 17, 2020
H6166
12 
•HR 6166 IH
and Congress can take to implement the rec-
1
ommendations described in subparagraph (B). 
2
(5) NO
COMPENSATION.—A member of the 
3
working group shall serve without compensation. 
4
(6) TERMINATION.—The working group shall 
5
terminate on the date on which the working group 
6
submits the report under paragraph (4). 
7
(7) CARDIOMYOPATHY
DEFINED.—For pur-
8
poses of this subsection, the term ‘‘cardiomyopathy’’ 
9
means a heart disease that affects the heart’s muscle 
10
(myocardium)— 
11
(A) the symptoms of which may vary from 
12
case to case, including— 
13
(i) cases in which no symptoms are 
14
present (asymptomatic); and 
15
(ii) cases in which there are symptoms 
16
of a progressive condition that may result 
17
from an impaired ability of the heart to 
18
pump blood, such as fatigue, irregular 
19
heartbeats (arrhythmia), heart failure, 
20
and, potentially, sudden cardiac death; and 
21
(B) the recognized types of which include 
22
dilated, hypertrophic, restrictive, arrhythmogen-
23
00:42 Mar 17, 2020
H6166
13 
•HR 6166 IH
ic right ventricular dysplasia, and left ventric-
1
ular non-compaction. 
2
Æ 
00:42 Mar 17, 2020
H6166
